August 5, 2019
In a first for immune checkpoint inhibitors, Roche/Chugai Pharmaceutical’s PD-L1 inhibitor Tecentriq (atezolizumab) cleared a key health ministry panel on August 2 for the treatment of small cell lung cancer (SCLC), putting it in line for Japanese approval as early...read more